Global Blood Therapeutics

We finally have new drugs for sickle cell disease. Why are so few patients taking them?
We finally have new drugs for sickle cell disease. Why are so few patients taking them?
Stat
sickle cell disease
patients
Global Blood Therapeutics
Oxbryta
Flag link:
Biopharma’s 5 Biggest M&A Deals of 2022
Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
M&A
Amgen
Horizon Therapeutics
Pfizer
Biohaven
Global Blood Therapeutics
Bristol Myers Squibb
Turning Point Therapeutics
ChemoCentryx
Flag link:
Pfizer’s dealmaking continues as GBT, Biohaven acquisitions close
Pfizer’s dealmaking continues as GBT, Biohaven acquisitions close
Medical Marketing and Media
Pfizer
M&A
Global Blood Therapeutics
Biohaven
Flag link:
No big bang for biopharma buyouts
No big bang for biopharma buyouts
EP Vantage
M&A
Pfizer
Global Blood Therapeutics
Amgen
ChemoCentryx
Novo Nordisk
Forma
Alcon
Aerie Pharmaceuticals
Gilead Sciences
MiroBio
Flag link:
Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: Bloomberg
Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: Bloomberg
Fierce Pharma
Pfizer
JNJ
M&A
Global Blood Therapeutics
Flag link:
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
BioPharma Dive
Pfizer
Global Blood Therapeutics
M&A
sickle cell disease
Oxbryta
Flag link:
Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics
Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics
Fierce Pharma
Pfizer
Global Blood Therapeutics
M&A
Oxbryta
Flag link:
Why Global Blood Therapeutics Trended Upward Today
Why Global Blood Therapeutics Trended Upward Today
Motley Fool
Global Blood Therapeutics
clinical trials
GBT601
sickle cell disease
Flag link:
Ash 2021 preview – small increases and big falls
Ash 2021 preview – small increases and big falls
EP Vantage
ASH2021
Sanofi
fitusiran
ALX Oncology
Syndax Pharma
Global Blood Therapeutics
IGM Biosciences
Flag link:
Global Blood takes on gene therapy
Global Blood takes on gene therapy
EP Vantage
Global Blood Therapeutics
GBT021601
Oxbryta
gene therapy
ASH2021
sickle cell disease
Flag link:
Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
Fierce Pharma
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
sickle cell disease
gene therapy
Flag link:
Fortunes diverge for solo drug launchers
Fortunes diverge for solo drug launchers
EP Vantage
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Flag link:
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
Endpoints
Sanofi
sickle cell disease
gene therapy
gene editing
Global Blood Therapeutics
Flag link:
New sickle cell drugs priced too high, ICER says
New sickle cell drugs priced too high, ICER says
BioPharma Dive
sickle cell disease
drug pricing
ICER
Novartis
Global Blood Therapeutics
RWE
Adakveo
Oxbryta
Flag link:
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
Fierce Pharma
Global Blood Therapeutics
drug launches
Oxbryta
sickle cell disease
HIV
Flag link:
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
Flag link:
5 biopharmas to watch as the decade's last earnings kick off
5 biopharmas to watch as the decade's last earnings kick off
BioPharma Dive
earnings
Novartis
Biogen
Eli Lilly
Global Blood Therapeutics
Bluebird Bio
Flag link:
3 Rare Disease Drug Launches to Watch in 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
Flag link:
5 New Drug Approvals the FDA Gave Top Priority
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:

Pages